Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 4Not yet recruiting 2Completed 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasms, Second Primary 1Breast Neoplasms 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Anthracyclines × 1 year × Clear all
NCT03199300 2025-12-11

InvestiCAT

University Medical Center Groningen

Active not recruiting
20 enrolled
Tumor-Agnostic

Neoplasms, Second Primary

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Lund University Hospital

Phase 3 Active not recruiting
325 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡